Determining up-to-date disease burden of 12 selected rare central nervous system tumors

Lire cet article en français

Takeaway

  • A partnership between the Central Brain Tumor Registry of the United States (CBTRUS) and the National Cancer Institute’s Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) yielded incidence and prevalence, as well as survival data, for rare brain and other central nervous system (CNS) tumors that had not previously been reported, which will provide a statistical basis for understanding and studying these tumors.

Why this matters

  • Understanding tumor-specific incidence, prevalence, and survival of rare primary brain and other CNS tumors is critical for evaluating the individual contribution of each tumor type to overall cancer burden.

  • These data can also be used as a statistical foundation in future clinical trials.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.